Bayer recalls mislabeled vials of hemophilia A treatment by Eric Palmer Tuesday, July 23, 2019 Bayer is recalling two lots of its top-selling drugs after a labeling mishap led to them being filled with the wrong hemophilia medicines.
Bayer's older meds deliver a surprisingly good show by Angus Liu Thursday, April 25, 2019 China sales and older meds helped boost Bayer's pharma results, but those numbers couldn't eclipse concerns about mushrooming Monsanto litigation.
9. Bayer by Angus Liu As Bayer completed the gigantic Monsanto crop science buyout in summer 2018, it started a large overhaul that will cut its animal health business, some consumer health brands and 10% of its workforce.
Launch of Novo's new hemophilia A drug delayed into 2020 by Angus Liu Thursday, February 21, 2019 Novo faces a tough task as several long-acting factor VIII therapies are already on the market, and Roche's antibody drug Hemlibra is zooming ahead.
Bayer to sell animal health, cut 12,000 jobs in huge overhaul by Angus Liu Thursday, November 29, 2018 A large-scale restructuring will touch every area of Bayer's business.
As Jivi launches, Bayer cuts 227 workers at U.S. plant that produces it by Eric Palmer Thursday, October 4, 2018 Bayer is laying off more than 225 workers at its complex in Berkeley, California, as it reorganizes manufacturing of its three hemophilia treatments.
